Hidradenitis Suppurativa: Emerging Targets and What the Pipeline Means for Your Patients

In this session from Masterclasses in Dermatology Saturday Morning Live, Dr Joseph Merola sits down with Dr Alice Gottlieb—dermatologist, rheumatologist, and one of the field's foremost experts in HS—for a focused clinical conversation on where HS treatment is headed.

Dr Gottlieb walks through the current unmet needs in HS care, from better systemic control and earlier intervention to access, stigma, and multidisciplinary coordination. From there, the conversation shifts to the emerging pipeline: nanobodies targeting IL-17A/F and TNF/OX40L, BTK inhibitor remibrutinib, JAK inhibitors povorcitinib and upadacitinib, dual IL-1 alpha/beta blockade with lutikizumab, and newer IL-1 beta-targeted agents with phase 2 data reported just days before this recording.

The discussion also covers combination therapy, the HS/Crohn's diagnostic overlap, procedural and surgical considerations, and the case for patient advocacy and reimbursement reform.

This episode is built for dermatologists, NPs, PAs, and any HCP managing patients with HS who wants a working knowledge of the treatment landscape right now—not a theoretical overview.

This podcast recording is for educational purposes only and does not offer CME credit. Want CME credit? Attend the next Saturday Morning Live session—free to register at mcdsml.com.

Thank you for listening.